Citations (166)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Noor A. Nahid & Julie A. Johnson. (2022) CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. Expert Opinion on Drug Metabolism & Toxicology 18:11, pages 769-785.
Read now
Read now
Ana Rita Silva & Ricardo Jorge Dinis-Oliveira. (2020) Pharmacokinetics and pharmacodynamics of dextromethorphan: clinical and forensic aspects. Drug Metabolism Reviews 52:2, pages 258-282.
Read now
Read now
Giuseppe Miscio, Giulia Paroni, Paola Bisceglia, Carolina Gravina, Maria Urbano, Madia Lozupone, Carla Piccininni, Michele Prisciandaro, Grazia Ciavarella, Antonio Daniele, Antonello Bellomo, Francesco Panza, Lazzaro Di Mauro, Antonio Greco & Davide Seripa. (2019) Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. Expert Opinion on Drug Metabolism & Toxicology 15:9, pages 751-765.
Read now
Read now
Yuan Ji, Yue Si, Gwendolyn A. McMillin & Elaine Lyon. (2018) Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine. Expert Review of Molecular Diagnostics 18:5, pages 411-421.
Read now
Read now
Jens Borggaard Larsen & Jan Borg Rasmussen. (2017) Pharmacogenetic testing revisited: 5′ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19. Pharmacogenomics and Personalized Medicine 10, pages 115-128.
Read now
Read now
Apichaya Puangpetch, Natchaya Vanwong, Nopphadol Nuntamool, Yaowaluck Hongkaew, Monpat Chamnanphon & Chonlaphat Sukasem. (2016) CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmacogenomics and Personalized Medicine 9, pages 131-147.
Read now
Read now
Wanaporn Charoenchokthavee, Duangchit Panomvana, Virote Sriuranpong & Nutthada Areepium. (2016) Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment. Breast Cancer: Targets and Therapy 8, pages 149-155.
Read now
Read now
Francesco Panza, Madia Lozupone, Eleonora Stella, Lucia Lofano, Carolina Gravina, Maria Urbano, Antonio Daniele, Antonello Bellomo, Giancarlo Logroscino, Antonio Greco & Davide Seripa. (2016) Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Review of Neurotherapeutics 16:12, pages 1357-1369.
Read now
Read now
Rashmi R. Shah. (2015) Inter-ethnic differences in drug response: Implications for drug development and complying with drug regulation. Clinical Research and Regulatory Affairs 32:3, pages 88-98.
Read now
Read now
Adrián LLerena, Maria Eugenia G Naranjo, Fernanda Rodrigues-Soares, Eva M Penas-LLedó, Humberto Fariñas & Eduardo Tarazona-Santos. (2014) Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opinion on Drug Metabolism & Toxicology 10:11, pages 1569-1583.
Read now
Read now
Britt I Drögemöller, Galen EB Wright & Louise Warnich. (2014) Considerations for rare variants in drug metabolism genes and the clinical implications. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 873-884.
Read now
Read now
Amtul H. Changasi, Tahireh A. Shams, Jennie G. Pouget & Daniel J. Müller. (2014) Genetics of antipsychotic drug outcome and implications for the clinician: into the limelight. Translational Developmental Psychiatry 2:1.
Read now
Read now
Articles from other publishers (154)
Zhan Ye, John Mayer, Emili J. Leary, Terrie Kitchner, Richard A. Dart, Murray H. Brilliant & Scott J. Hebbring. (2023) Estimating the efficacy of pharmacogenomics over a lifetime. Frontiers in Medicine 10.
Crossref
Crossref
Aaron D. Besterman. (2023) A genetics-guided approach to the clinical management of schizophrenia. Schizophrenia Research.
Crossref
Crossref
Skokhrukh P. Abdullaev, Maksim N. Shatokhin, Svetlana N. Tuchkova, Sherzod P. Abdullaev, Oleg V. Teodorovich, Oleg B. Loran & Dmitry A. Sychev. (2023) Effects of CYP2D6 allelic variants on therapy with tamsulosin in patients with benign prostatic hyperplasia. Drug Metabolism and Personalized Therapy 0:0.
Crossref
Crossref
Amy J. Turner, Ashley D. Derezinski, Andrea Gaedigk, Mark E. Berres, David B. Gregornik, Keith Brown, Ulrich Broeckel & Gunter Scharer. (2023) Characterization of complex structural variation in the CYP2D6-CYP2D7-CYP2D8 gene loci using single-molecule long-read sequencing. Frontiers in Pharmacology 14.
Crossref
Crossref
Shotaro Uehara, Yuichiro Higuchi, Nao Yoneda, Ryoji Ito, Takeshi Takahashi, Norie Murayama, Hiroshi Yamazaki, Kazuhiro Murai, Hayato Hikita, Tetsuo Takehara & Hiroshi Suemizu. (2023) HepaSH cells: Experimental human hepatocytes with lesser inter-individual variation and more sustainable availability than primary human hepatocytes. Biochemical and Biophysical Research Communications 663, pages 132-141.
Crossref
Crossref
Guang Yang, Mrinal Mishra & Minoli A. Perera. (2023) Multi‐Omics Studies in Historically Excluded Populations: The Road to Equity. Clinical Pharmacology & Therapeutics 113:3, pages 541-556.
Crossref
Crossref
Di Fu, Hong-Li Guo, Ya-Hui Hu, Wei-Rong Fang, Qian-Qi Liu, Jing Xu, Dan-Dan Wu & Feng Chen. (2023) Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence. European Journal of Clinical Pharmacology.
Crossref
Crossref
Yasmeen Kawji, Hanna Almoaswes, Claire A. Bise, Lena Kawji, Adrienne M. Murphy, Tanner D. Reed, Amber N. Edinoff, Elyse M. Cornett & Alan David Kaye. 2023. Substance Use and Addiction Research. Substance Use and Addiction Research
333
347
.
J. Kevin Hicks. 2023. Chronic Illness Care. Chronic Illness Care
3
17
.
Anmar AL-Taie, Ayşe Şeyma Büyük & Semra Sardas. (2022) Considerations into pharmacogenomics of COVID-19 pharmacotherapy: Hope, hype and reality. Pulmonary Pharmacology & Therapeutics 77, pages 102172.
Crossref
Crossref
Shobha Elizabeth Satkunananthan, Vijayaprakash Suppiah, Gaik-Theng Toh & Hui-Yin Yow. (2022) Pharmacogenomics of Cancer Pain Treatment Outcomes in Asian Populations: A Review. Journal of Personalized Medicine 12:11, pages 1927.
Crossref
Crossref
Anita Stojanović Marković, Matea Zajc Petranović, Tatjana Škarić-Jurić, Željka Celinšćak, Maja Šetinc, Željka Tomas & Marijana Peričić Salihović. (2022) Relevance of CYP2D6 Gene Variants in Population Genetic Differentiation. Pharmaceutics 14:11, pages 2481.
Crossref
Crossref
Jan Grzegorzewski, Janosch Brandhorst & Matthias König. (2022) Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan. Frontiers in Pharmacology 13.
Crossref
Crossref
Wouroud Ismail Al-khalil, Lana Al-Salhi, Sara Rijjal, Majd Aljamali & Lama A. Youssef. (2022) The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. BMC Cancer 22:1.
Crossref
Crossref
Emily J Cicali & Kristin Wiisanen. (2022)
The importance of phenoconversion when using the
CYP2D6
genotype in clinical practice
. Pharmacogenomics 23:14, pages 749-752.
Crossref
Crossref
Simon Verdez, Juliette Albuisson, Yannis Duffourd, Romain Boidot, Manon Reda, Christel Thauvin-Robinet, Jean-David Fumet, Sylvain Ladoire, Sophie Nambot, Patrick Callier, Laurence Faivre, François Ghiringhelli & Nicolas Picard. (2022) Detection of relevant pharmacogenetic information through exome sequencing in oncology. Pharmacogenomics 23:14, pages 759-770.
Crossref
Crossref
Ye Jin, Shuquan Zhang, Pei Hu, Xin Zheng, Xiaoduo Guan, Rui Chen & Shuyang Zhang. (2022) The impact of CYP2D6*41 on CYP2D6 enzyme activity using phenotyping methods in urine, plasma, and saliva. Frontiers in Pharmacology 13.
Crossref
Crossref
Seung-been Lee, Jong-Yeon Shin, Nak-Jung Kwon, Changhoon Kim & Jeong-Sun Seo. (2022) ClinPharmSeq: A targeted sequencing panel for clinical pharmacogenetics implementation. PLOS ONE 17:7, pages e0272129.
Crossref
Crossref
Santiago Silva-Alarcon, Claudia Valencia, Lyle Newball, Wilmar Saldarriaga & Andres Castillo. (2022) Molecular Variants in Genes related to the Response to Ocular Hypotensive Drugs in an Afro-Colombian Population. The Open Ophthalmology Journal 16:1.
Crossref
Crossref
Beata Franczyk, Jacek Rysz, Jarosław Miłoński, Tomasz Konecki, Magdalena Rysz-Górzyńska & Anna Gluba-Brzózka. (2022) Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. Pharmaceuticals 15:6, pages 739.
Crossref
Crossref
Yong-Hang Li, Wei Huang, Man-Yu Xiao, Shi-Qing Huang, Hui Chen, Zai-Fang Li, Xue-Song Li & Yong Cheng. (2022) CYP2D6 Gene Polymorphisms and Variable Metabolic Activity in Schizophrenia Patients of Han and Tibetan Populations. Neuropsychiatric Disease and Treatment Volume 18, pages 731-736.
Crossref
Crossref
S. Sahana, Rahul C. Bhoyar, Ambily Sivadas, Abhinav Jain, Mohamed Imran, Mercy Rophina, Vigneshwar Senthivel, Mohit Kumar Diwakar, Disha Sharma, Anushree Mishra, Sridhar Sivasubbu & Vinod Scaria. (2022) Pharmacogenomic landscape of Indian population using whole genomes. Clinical and Translational Science 15:4, pages 866-877.
Crossref
Crossref
Anita Stojanović Marković, Matea Zajc Petranović, Željka Tomas, Borna Puljko, Maja Šetinc, Tatjana Škarić-Jurić & Marijana Peričić Salihović. (2022) Untangling SNP Variations within CYP2D6 Gene in Croatian Roma. Journal of Personalized Medicine 12:3, pages 374.
Crossref
Crossref
Mousa Alali, Wouroud Ismail Al-khalil, Sara Rijjal, Lana Al-Salhi, Maher Saifo & Lama A. Youssef. (2022) Frequencies of CYP2D6 genetic polymorphisms in Arab populations. Human Genomics 16:1.
Crossref
Crossref
Maaike van der Lee, William J. Rowell, Roberta Menafra, Henk-Jan Guchelaar, Jesse J. Swen & Seyed Yahya Anvar. (2021) Application of long-read sequencing to elucidate complex pharmacogenomic regions: a proof of principle. The Pharmacogenomics Journal 22:1, pages 75-81.
Crossref
Crossref
Chia-Yuan Chen, Chi-Hsiang Chung, Wu-Chien Chien & Hsin-Chien Chen. (2022) The Association Between Dextromethorphan Use and the Risk of Dementia. American Journal of Alzheimer's Disease & Other Dementias® 37, pages 153331752211249.
Crossref
Crossref
Gabriel Eckermann. 2022. Elsevier Essentials Migration & Gesundheit. Elsevier Essentials Migration & Gesundheit
155
158
.
Anuradha Ramamoorthy, Tristan Sissung & Michael Pacanowski. 2022. Atkinson's Principles of Clinical Pharmacology. Atkinson's Principles of Clinical Pharmacology
189
212
.
Gaëlle Magliocco, Jules Desmeules, Alain Matthey, Luis M. Quirós‐Guerrero, Nasim Bararpour, Timothée Joye, Laurence Marcourt, Emerson F. Queiroz, Jean‐Luc Wolfender, Yvonne Gloor, Aurélien Thomas & Youssef Daali. (2021) Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity. British Journal of Pharmacology 178:23, pages 4708-4725.
Crossref
Crossref
Maaike van der Lee, Henk-Jan Guchelaar & Jesse J Swen. (2021) Substrate specificity of CYP2D6 genetic variants. Pharmacogenomics 22:16, pages 1081-1089.
Crossref
Crossref
Madeleine C. Allen, Nora K. Moog, Claudia Buss, Elizabeth Yen, Hanna C. Gustafsson, Elinor L. Sullivan & Alice M. Graham. (2021) Co-occurrence of preconception maternal childhood adversity and opioid use during pregnancy: Implications for offspring brain development. Neurotoxicology and Teratology 88, pages 107033.
Crossref
Crossref
Trine Frederiksen, Robert L. Smith, Birgit M. Wollmann, Johan Areberg & Espen Molden. (2021) Validation of a Population Pharmacokinetic Model of Vortioxetine Using Therapeutic Drug Monitoring Data. Clinical Pharmacokinetics 60:11, pages 1475-1486.
Crossref
Crossref
Catherine R. Virelli, Ayeshah G. Mohiuddin & James L. Kennedy. (2021) Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis. Translational Psychiatry 11:1.
Crossref
Crossref
Sze Wa Chan, Tanya T. W. Chu, Chung Shun Ho, Alice P. S. Kong, Brian Tomlinson & Weiwei Zeng. (2021) Influence of CYP2D6 and CYP3A5 Polymorphisms on the Pharmacokinetics and Pharmacodynamics of Bisoprolol in Hypertensive Chinese Patients. Frontiers in Medicine 8.
Crossref
Crossref
Victoria M. Pratt, Larisa H. Cavallari, Andria L. Del Tredici, Andrea Gaedigk, Houda Hachad, Yuan Ji, Lisa V. Kalman, Reynold C. Ly, Ann M. Moyer, Stuart A. Scott, R.H.N. van Schaik, Michelle Whirl-Carrillo & Karen E. Weck. (2021) Recommendations for Clinical CYP2D6 Genotyping Allele Selection. The Journal of Molecular Diagnostics 23:9, pages 1047-1064.
Crossref
Crossref
Emily J. Cicali, Amanda L. Elchynski, Kelsey J. Cook, John T. Houder, Cameron D. Thomas, D. Max Smith, Amanda Elsey, Julie A. Johnson, Larisa H. Cavallari & Kristin Wiisanen. (2021) How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial. Clinical Pharmacology & Therapeutics 110:3, pages 677-687.
Crossref
Crossref
Farhana Islam, Xiaoyu Men, Kazunari Yoshida, Clement C. Zai & Daniel J. Müller. (2021) Pharmacogenetics‐Guided Advances in Antipsychotic Treatment. Clinical Pharmacology & Therapeutics 110:3, pages 582-588.
Crossref
Crossref
Maaike van der Lee, William G. AllardRolf H. A. M. VossenRenée F. Baak-PabloRoberta Menafra, Birgit A. L. M. Deiman, Maarten J. Deenen, Patrick NevenInger JohanssonStefano Gastaldello, Magnus Ingelman-SundbergHenk-Jan Guchelaar, Jesse J. Swen & Seyed Yahya Anvar. (2021)
Toward predicting CYP2D6-mediated variable drug response from
CYP2D6
gene sequencing data
. Science Translational Medicine 13:603.
Crossref
Crossref
Yaowaluck Hongkaew, Wendy Y Wang, Roger Gaedigk, Chonlaphat Sukasem & Andrea Gaedigk. (2021)
Resolving discordant
CYP2D6
genotyping results in Thai subjects: platform limitations and novel haplotypes
. Pharmacogenomics 22:9, pages 529-541.
Crossref
Crossref
Patrick Vizeli, Isabelle Straumann, Friederike Holze, Yasmin Schmid, Patrick C. Dolder & Matthias E. Liechti. (2021) Genetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis. Scientific Reports 11:1.
Crossref
Crossref
Amy J. Turner, Praful Aggarwal, Erin C. Boone, Cyrine-Eliana Haidar, Mary V. Relling, Ashley D. Derezinski, Ulrich Broeckel & Andrea Gaedigk. (2021) Identification of CYP2D6 Haplotypes that Interfere with Commonly Used Assays for Copy Number Variation Characterization. The Journal of Molecular Diagnostics 23:5, pages 577-588.
Crossref
Crossref
Espen Molden & Marin M. Jukić. (2021) CYP2D6 Reduced Function Variants and Genotype/Phenotype Translations of CYP2D6 Intermediate Metabolizers: Implications for Personalized Drug Dosing in Psychiatry. Frontiers in Pharmacology 12.
Crossref
Crossref
Thuraya M Mutawi, Mohamed M Zedan, Raida S Yahya, Mahmoud M Zakria, Mamdouh R El-Sawi & Andrea Gaedigk. (2021)
Genetic variability of
CYP2D6, CYP3A4
and
CYP3A5
among the Egyptian population
. Pharmacogenomics 22:6, pages 323-334.
Crossref
Crossref
Xiao Chen, Fei Shen, Nina Gonzaludo, Alka Malhotra, Cande Rogert, Ryan J. Taft, David R. Bentley & Michael A. Eberle. (2021) Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data. The Pharmacogenomics Journal 21:2, pages 251-261.
Crossref
Crossref
Ingrid Fricke-Galindo & Ramcés Falfán-Valencia. (2021) Pharmacogenetics Approach for the Improvement of COVID-19 Treatment. Viruses 13:3, pages 413.
Crossref
Crossref
Martina Hahn, Daniel J. Müller & Sibylle C. Roll. (2020) Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. Pharmacopsychiatry 54:02, pages 81-89.
Crossref
Crossref
Gualberto Ruaño, Joseph Tortora, Saskia Robinson, Seth Baker, Theodore Holford, Andrew Winokur & John W. Goethe. (2021) Subanalysis of the CYP-GUIDES Trial: CYP2D6 Functional Stratification and Operational Timeline Selection. Psychiatry Research 297, pages 113571.
Crossref
Crossref
Yaowaluck Hongkaew, Andrea Gaedigk, Bob Wilffert, Nattawat Ngamsamut, Wiranpat Kittitharaphan, Penkhae Limsila & Chonlaphat Sukasem. (2021) Relationship between CYP2D6 genotype, activity score and phenotype in a pediatric Thai population treated with risperidone. Scientific Reports 11:1.
Crossref
Crossref
Koya Fukunaga, Eiji Hishinuma, Masahiro Hiratsuka, Ken Kato, Takuji Okusaka, Takeo Saito, Masashi Ikeda, Teruhiko Yoshida, Hitoshi Zembutsu, Nakao Iwata & Taisei Mushiroda. (2020) Determination of novel CYP2D6 haplotype using the targeted sequencing followed by the long-read sequencing and the functional characterization in the Japanese population. Journal of Human Genetics 66:2, pages 139-149.
Crossref
Crossref
Rocío Núñez-Torres & Anna González-Neira. 2021. Clinical DNA Variant Interpretation. Clinical DNA Variant Interpretation
193
219
.
Uttam Garg, Tracy L. Sandritter & Andrea Gaedigk. 2021. Biochemical and Molecular Basis of Pediatric Disease. Biochemical and Molecular Basis of Pediatric Disease
849
908
.
Simeon Rüdesheim, Jan-Georg Wojtyniak, Dominik Selzer, Nina Hanke, Felix Mahfoud, Matthias Schwab & Thorsten Lehr. (2020) Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics 12:12, pages 1200.
Crossref
Crossref
Maaike van der Lee, Marjolein Kriek, Henk-Jan Guchelaar & Jesse J. Swen. (2020) Technologies for Pharmacogenomics: A Review. Genes 11:12, pages 1456.
Crossref
Crossref
Gregory McInnes, Rachel Dalton, Katrin Sangkuhl, Michelle Whirl-Carrillo, Seung-been Lee, Philip S. Tsao, Andrea Gaedigk, Russ B. Altman & Erica L. Woodahl. (2020) Transfer learning enables prediction of CYP2D6 haplotype function. PLOS Computational Biology 16:11, pages e1008399.
Crossref
Crossref
Christopher Taylor, Ian Crosby, Vincent Yip, Peter Maguire, Munir Pirmohamed & Richard M. Turner. (2020) A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes 11:11, pages 1295.
Crossref
Crossref
David Twesigomwe, Galen E. B. Wright, Britt I. Drögemöller, Jorge da Rocha, Zané Lombard & Scott Hazelhurst. (2020) A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: a focus on CYP2D6 genotyping. npj Genomic Medicine 5:1.
Crossref
Crossref
Tal Gilboa, Padric M. Garden & Limor Cohen. (2020) Single-molecule analysis of nucleic acid biomarkers – A review. Analytica Chimica Acta 1115, pages 61-85.
Crossref
Crossref
Cole Tolledo, Marlaina R. Stocco, Sharon Miksys, Frank J. Gonzalez & Rachel F. Tyndale. (2020) Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice. Molecular Neurobiology 57:6, pages 2509-2520.
Crossref
Crossref
Lisa B. Namerow, Sophia A. Walker, Mirela Loftus, Jeffrey R. Bishop, Gualberto Ruaño & Salma Malik. (2020) Pharmacogenomics: an Update for Child and Adolescent Psychiatry. Current Psychiatry Reports 22:5.
Crossref
Crossref
Muslih Abdulkarim Ibrahim, Zalina Zahari, Nurfadhlina Musa & Khoo Boon Yin. (2020) Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds. Current Pharmacogenomics and Personalized Medicine 17:1, pages 40-47.
Crossref
Crossref
Roos van Westrhenen, Katherine J. Aitchison, Magnus Ingelman-Sundberg & Marin M. Jukić. (2020) Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. Frontiers in Psychiatry 11.
Crossref
Crossref
Edgor Cole Tolledo, Sharon Miksys, Frank J. Gonzalez & Rachel F. Tyndale. (2020) Propranolol is a mechanism‐based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6‐transgenic mice: Effects on activity and drug responses. British Journal of Pharmacology 177:3, pages 701-712.
Crossref
Crossref
Gualberto Ruaño, Saskia Robinson, Theodore Holford, Raveen Mehendru, Seth Baker, Joseph Tortora & John W. Goethe. (2020) Results of the CYP-GUIDES randomized controlled trial: Total cohort and primary endpoints. Contemporary Clinical Trials 89, pages 105910.
Crossref
Crossref
Ádám Kiss, Ádám Menus, Katalin Tóth, Máté Déri, Dávid Sirok, Evelyn Gabri, Ales Belic, Gábor Csukly, István Bitter & Katalin Monostory. (2019) Phenoconversion of CYP2D6 by inhibitors modifies aripiprazole exposure. European Archives of Psychiatry and Clinical Neuroscience 270:1, pages 71-82.
Crossref
Crossref
Rachel Dalton, Seung‐been Lee, Katrina G. Claw, Bhagwat Prasad, Brian R. Phillips, Danny D. Shen, Lai Hong Wong, Mitch Fade, Matthew G. McDonald, Maitreya J. Dunham, Douglas M. Fowler, Allan E. Rettie, Erin Schuetz, Timothy A. Thornton, Deborah A. Nickerson, Andrea Gaedigk, Kenneth E. Thummel & Erica L. Woodahl. (2019)
Interrogation of
CYP
2D6
Structural Variant Alleles Improves the Correlation Between
CYP
2D6
Genotype and
CYP
2D6‐Mediated Metabolic Activity
. Clinical and Translational Science 13:1, pages 147-156.
Crossref
Crossref
Milad Webb & Jeffrey Jentzen. 2020. Toxicology Cases for the Clinical and Forensic Laboratory. Toxicology Cases for the Clinical and Forensic Laboratory
113
116
.
Charity Nofziger, Amy J. Turner, Katrin Sangkuhl, Michelle Whirl‐Carrillo, José A.G. Agúndez, John L. Black, Henry M. Dunnenberger, Gualberto Ruano, Martin A. Kennedy, Michael S. Phillips, Houda Hachad, Teri E. Klein & Andrea Gaedigk. (2019)
PharmVar GeneFocus:
CYP2D6
. Clinical Pharmacology & Therapeutics 107:1, pages 154-170.
Crossref
Crossref
Lauren A. Marcath, Amy L. Pasternak & Daniel L. Hertz. (2019) Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. The Pharmacogenomics Journal 19:6, pages 501-515.
Crossref
Crossref
Seung‐been Lee, Marsha M. Wheeler, Kenneth E. Thummel & Deborah A. Nickerson. (2019) Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. Clinical Pharmacology & Therapeutics 106:6, pages 1328-1337.
Crossref
Crossref
Steven E. Scherer. (2019) The Evolution of DNA Sequencing in Pharmacogenomics. Advances in Molecular Pathology 2:1, pages 119-131.
Crossref
Crossref
Andrea Gaedigk, Amy Turner, Robin E. Everts, Stuart A. Scott, Praful Aggarwal, Ulrich Broeckel, Gwendolyn A. McMillin, Roberta Melis, Erin C. Boone, Victoria M. Pratt & Lisa V. Kalman. (2019) Characterization of Reference Materials for Genetic Testing of CYP2D6 Alleles. The Journal of Molecular Diagnostics 21:6, pages 1034-1052.
Crossref
Crossref
Michele D Spring, Jason C Sousa, Qigui Li, Christian A Darko, Meshell N Morrison, Sean R Marcsisin, Kristin T Mills, Brittney M Potter, Kristopher M Paolino, Patrick S Twomey, James E Moon, Donna M Tosh, Susan B Cicatelli, Jeffrey W Froude, Brandon S Pybus, Thomas G Oliver, William F McCarthy, Norman C Waters, Philip L Smith, Gregory A Reichard & Jason W Bennett. (2019) Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population. The Journal of Infectious Diseases 220:11, pages 1761-1770.
Crossref
Crossref
Miho Imai, Madoka Kisoi, Miwako Moritsugu, Shigenori Murata, Atsushi Ichikawa & Kenji Kinoshita. (2019) Development of an Inexpensive and Rapid Operation Device for High-Throughput Real-Time Quantitative PCR-Based <i>CYP2D6</i> CNV Genotyping. Biological and Pharmaceutical Bulletin 42:10, pages 1761-1765.
Crossref
Crossref
Iris Tatjana Graef-Calliess, Umut Altunöz & Madleen Golz. (2019) Patienten kultursensibel behandeln. DNP - Der Neurologe & Psychiater 20:5, pages 36-45.
Crossref
Crossref
Yusmiati Liau, Simran Maggo, Allison L Miller, John F Pearson, Martin A Kennedy & Simone L Cree. (2019)
Nanopore sequencing of the pharmacogene
CYP2D6
allows simultaneous haplotyping and detection of duplications
. Pharmacogenomics 20:14, pages 1033-1047.
Crossref
Crossref
Hippman & Nislow. (2019) Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. Journal of Personalized Medicine 9:3, pages 40.
Crossref
Crossref
Gualberto Ruaño, Theodore Holford, Richard L. Seip, John W. Goethe & Raveen Mehendru. (2019) Pharmacogenetic clinical decision support for psychiatric hospitalization: Design of the CYP-GUIDES randomized controlled trial. Contemporary Clinical Trials 83, pages 27-36.
Crossref
Crossref
Honghong Zhang, Tanima De, Yizhen Zhong & Minoli A. Perera. (2019) The Advantages and Challenges of Diversity in Pharmacogenomics: Can Minority Populations Bring Us Closer to Implementation?. Clinical Pharmacology & Therapeutics 106:2, pages 338-349.
Crossref
Crossref
Miaoran Ning, Julio D. Duarte, Faith Stevison, Nina Isoherranen, Leah H. Rubin & Hyunyoung Jeong. (2019)
Determinants of Cytochrome P450 2D6
mRNA
Levels in Healthy Human Liver Tissue
. Clinical and Translational Science 12:4, pages 416-423.
Crossref
Crossref
Yaqiong Jin, Geng Chen, Wenming Xiao, Huixiao Hong, Joshua Xu, Yongli Guo, Wenzhong Xiao, Tieliu Shi, Leming Shi, Weida Tong & Baitang Ning. (2019) Sequencing XMET genes to promote genotype-guided risk assessment and precision medicine. Science China Life Sciences 62:7, pages 895-904.
Crossref
Crossref
Joseph P. Jarvis, Arul Prakasam Peter & Jeffrey A. Shaman. (2019) Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry. Frontiers in Psychiatry 10.
Crossref
Crossref
Kazeem A. Oshikoya, Katelyn M. Neely, Robert J. Carroll, Ida T. Aka, Angela C. Maxwell-Horn, Dan M. Roden & Sara L. Van Driest. (2019) CYP2D6 genotype and adverse events to risperidone in children and adolescents. Pediatric Research 85:5, pages 602-606.
Crossref
Crossref
Ahmed T. Ahmed, Joanna M. Biernacka, Gregory Jenkins, A John Rush, Gen Shinozaki, Marin Veldic, Simon Kung, William V. Bobo, Daniel K. Hall-Flavin, Richard M. Weinshilboum, Liewei Wang & Mark A. Frye. (2019) Pharmacokinetic-Pharmacodynamic interaction associated with venlafaxine-XR remission in patients with major depressive disorder with history of citalopram / escitalopram treatment failure. Journal of Affective Disorders 246, pages 62-68.
Crossref
Crossref
Ute I. Schwarz, Markus Gulilat & Richard B. Kim. (2019) The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics. Cold Spring Harbor Perspectives in Medicine 9:2, pages a033027.
Crossref
Crossref
Balmiki Ray, Eren Ozcagli, Wolfgang Sadee & Danxin Wang. (2019) CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele). Pharmacogenetics and Genomics 29:2, pages 39-47.
Crossref
Crossref
Wanqiong Qiao, Suparna Martis, Geetu Mendiratta, Lisong Shi, Mariana R Botton, Yao Yang, Andrea Gaedigk, Raymon Vijzelaar, Lisa Edelmann, Ruth Kornreich, Robert J Desnick & Stuart A Scott. (2019)
Integrated
CYP2D6
interrogation for multiethnic copy number and tandem allele detection
. Pharmacogenomics 20:1, pages 9-20.
Crossref
Crossref
Wing Chan, Man S. Li, Senthil K. Sundaram, Brian Tomlinson, Pik Y. Cheung & Chi H. Tzang. (2018)
CYP2D6
allele frequencies, copy number variants, and tandems in the population of Hong Kong
. Journal of Clinical Laboratory Analysis 33:1.
Crossref
Crossref
Thomas Dodsworth, David D. Kim, Ric M. Procyshyn, Colin J. Ross, William G. Honer & Alasdair M. Barr. (2018) A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child and Adolescent Psychiatry and Mental Health 12:1.
Crossref
Crossref
Kanokpich Puaprasert, Cindy Chu, Naowarat Saralamba, Nicholas P. J. Day, Francois Nosten, Nicholas J. White, Arjen M. Dondorp & Mallika Imwong. (2018) Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study. Malaria Journal 17:1.
Crossref
Crossref
Miaoran Ning, Julio D. Duarte, Leah H. Rubin & Hyunyoung Jeong. (2018) CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6‐Mediated Drug Metabolism in Healthy Human Liver Tissue. Clinical Pharmacology & Therapeutics 104:5, pages 974-982.
Crossref
Crossref
Charleen G. Don & Martin Smieško. (2018) Out‐compute drug side effects: Focus on cytochrome P450 2D6 modeling. WIREs Computational Molecular Science 8:5.
Crossref
Crossref
Manuel A. Franco-Martin, Francisco Sans, Belen García-Berrocal, Cristina Blanco, Carlos Llanes-Alvarez & María Isidoro-García. (2018) Usefulness of Pharmacogenetic Analysis in Psychiatric Clinical Practice: A Case Report. Clinical Psychopharmacology and Neuroscience 16:3, pages 349-357.
Crossref
Crossref
Charity Nofziger & Markus Paulmichl. (2018)
Accurately genotyping
CYP2D6
: not for the faint of heart
. Pharmacogenomics 19:13, pages 999-1002.
Crossref
Crossref
Monpat Chamnanphon, Andrea Gaedigk, Natchaya Vanwong, Nopphadol Nuntamool, Yaowaluck Hongkaew, Apichaya Puangpetch & Chonlaphat Sukasem. (2018)
CYP2D6
genotype analysis of a Thai population: platform comparison
. Pharmacogenomics 19:12, pages 947-960.
Crossref
Crossref
Clement C. Zai, Arun K. Tiwari, Gwyneth C. Zai, Miriam S. Maes & James L. Kennedy. (2018) New findings in pharmacogenetics of schizophrenia. Current Opinion in Psychiatry 31:3, pages 200-212.
Crossref
Crossref
M E Moretti, D F Lato, H Berger, G Koren, S Ito & W J Ungar. (2017) A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events. The Pharmacogenomics Journal 18:3, pages 391-397.
Crossref
Crossref
Andrea Gaedigk, Jean Dinh, Hyunyoung Jeong, Bhagwat Prasad & J. Leeder. (2018) Ten Years’ Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics. Journal of Personalized Medicine 8:2, pages 15.
Crossref
Crossref
Lazara Karelia Montané Jaime, Jeffrey Paul, Anthony Lalla, George Legall & Andrea Gaedigk. (2018)
Impact of
CYP2D6
on venlafaxine metabolism in Trinidadian patients with major depressive disorder
. Pharmacogenomics 19:3, pages 197-212.
Crossref
Crossref
Ádám Ferenc Kiss, Katalin Tóth, Cintia Juhász, Manna Temesvári, József Paulik, Gábor Hirka & Katalin Monostory. (2018) Is CYP2D6 phenotype predictable from CYP2D6 genotype?. Microchemical Journal 136, pages 209-214.
Crossref
Crossref
Deirdre P. Cronin-Fenton & Per Damkier. 2018. Pharmacogenetics. Pharmacogenetics
65
91
.
Gwendolyn A. McMillin, Mia Wadelius & Victoria M. Pratt. 2018. Principles and Applications of Molecular Diagnostics. Principles and Applications of Molecular Diagnostics
295
327
.
K.K. Wolf & M.F. Paine. 2018. Comprehensive Toxicology. Comprehensive Toxicology
74
98
.
J. Kevin Hicks & Henry M. Dunnenberger. 2018. Chronic Illness Care. Chronic Illness Care
3
16
.
Theodore Wigle, Laura Jansen, Wendy Teft & Richard Kim. (2017) Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. Journal of Personalized Medicine 7:4, pages 20.
Crossref
Crossref
Anil S Modak. (2017) Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need. Journal of Breath Research 12:1, pages 017101.
Crossref
Crossref
Hye In Woo, Se Kyung Lee, Jiyoung Kim, Seok Won Kim, Jonghan Yu, Soo Youn Bae, Jeong Eon Lee, Seok Jin Nam & Soo-Youn Lee. (2017) Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget 8:59, pages 100296-100311.
Crossref
Crossref
Xiaofeng Gao, Huan Wang & Hui Chen. (2017)
Impact of
CYP2D6
and
ADRB1
polymorphisms on heart rate of post-PCI patients treated with metoprolol
. Pharmacogenomics.
Crossref
Crossref
Teresa T. Vo, Gillian C. Bell, Aniwaa Owusu Obeng, J. Kevin Hicks & Henry M. Dunnenberger. (2017) Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37:9, pages 1014-1022.
Crossref
Crossref
W Qiao, J Wang, B S Pullman, R Chen, Y Yang & S A Scott. (2016) The CYP2D6 VCF Translator. The Pharmacogenomics Journal 17:4, pages 301-303.
Crossref
Crossref
Mirjam Simoons, Hans Mulder, Robert A Schoevers, Henricus G Ruhé & Eric N van Roon. (2017)
Availability of
CYP2D6
genotyping results in general practitioner and community pharmacy medical records
. Pharmacogenomics 18:9, pages 843-851.
Crossref
Crossref
Rui Chen, Xin Zheng & Pei Hu. (2017) CYP2D6 Phenotyping Using Urine, Plasma, and Saliva Metabolic Ratios to Assess the Impact of CYP2D6∗10 on Interindividual Variation in a Chinese Population. Frontiers in Pharmacology 8.
Crossref
Crossref
Yao Yang, Mariana R Botton, Erick R Scott & Stuart A Scott. (2017)
Sequencing the
CYP2D6
gene: from variant allele discovery to clinical pharmacogenetic testing
. Pharmacogenomics 18:7, pages 673-685.
Crossref
Crossref
Jacob T Brown, Mark Schneiderhan, Seenae Eum & Jeffrey R Bishop. (2017) Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics 18:7, pages 601-605.
Crossref
Crossref
T. Bschor, C. Baethge, C. Hiemke & B. Müller-Oerlinghausen. (2017) Genetische Tests zur Steuerung der Behandlung mit AntidepressivaGenetic tests for controlling treatment with antidepressants. Der Nervenarzt 88:5, pages 495-499.
Crossref
Crossref
Célia Lloret-Linares, Victoria Rollason, Kuntheavy Ing Lorenzini, Caroline Samer, Youssef Daali, Marianne Gex-Fabry, Jean-Michel Aubry, Jules Desmeules & Marie Besson. (2017) Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. Pharmacological Research 118, pages 104-110.
Crossref
Crossref
Natchaya VanwongNattawat NgamsamutSadeep MedhasiApichaya PuangpetchMontri ChamnanphonTeerarat Tan-kamYaowaluck HongkaewPenkhae LimsilaChonlaphat Sukasem. (2017) Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. Journal of Child and Adolescent Psychopharmacology 27:2, pages 185-191.
Crossref
Crossref
Henk P.J. Buermans, Rolf H.A.M. Vossen, Seyed Yahya Anvar, William G. Allard, Henk-Jan Guchelaar, Stefan J. White, Johan T. den Dunnen, Jesse J. Swen & Tahar van der Straaten. (2017) Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing. Human Mutation 38:3, pages 310-316.
Crossref
Crossref
T M Dodgen, C De J Labuschagne, A van Schalkwyk, F E Steffens, A Gaedigk, A D Cromarty, M Alessandrini & M S Pepper. (2015) Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort. The Pharmacogenomics Journal 16:6, pages 566-572.
Crossref
Crossref
Cristy Eidelman & Susan M Abdel-Rahman. (2016) Pharmacokinetic considerations when prescribing in children. International Journal of Pharmacokinetics 1:1, pages 69-80.
Crossref
Crossref
MJ Arwood, S Chumnumwat, LH Cavallari, EA Nutescu & JD Duarte. (2016) Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges. Clinical and Translational Science 9:5, pages 233-245.
Crossref
Crossref
Rui Chen, Amin Rostami-Hodjegan, Haotian Wang, David Berk, Jun Shi & Pei Hu. (2016) Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6. European Journal of Pharmaceutical Sciences 92, pages 131-136.
Crossref
Crossref
Rania Naoufal, Marine Legendre, Dominique Couet, Brigitte Gilbert-Dussardier, Alain Kitzis, Frederic Bilan & Radu Harbuz. (2016) Association of structural and numerical anomalies of chromosome 22 in a patient with syndromic intellectual disability. European Journal of Medical Genetics 59:9, pages 483-487.
Crossref
Crossref
Rachel K Lanning, Clement C Zai & Daniel J Müller. (2016) Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics 17:12, pages 1339-1351.
Crossref
Crossref
Almudena Sánchez-Martín, Santiago Sánchez-Iglesias, Belén García-Berrocal, Carolina Lorenzo, Andrea Gaedigk & María Isidoro-García. (2016)
Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder:
CYP2D6
. Pharmacogenomics 17:12, pages 1291-1293.
Crossref
Crossref
Suzana Fonseca, António Amorim, Heloísa Afonso Costa, João Franco, Maria João Porto, Jorge Costa Santos & Mário Dias. (2016) Sequencing CYP2D6 for the detection of poor-metabolizers in post-mortem blood samples with tramadol. Forensic Science International 265, pages 153-159.
Crossref
Crossref
Malik Nassan, Wayne T. Nicholson, Michelle A. Elliott, Carolyn R. Rohrer Vitek, John L. Black & Mark A. Frye. (2016) Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Mayo Clinic Proceedings 91:7, pages 897-907.
Crossref
Crossref
Volker M Lauschke & Magnus Ingelman-Sundberg. (2016) Requirements for comprehensive pharmacogenetic genotyping platforms. Pharmacogenomics 17:8, pages 917-924.
Crossref
Crossref
Gualberto Ruaño, Mohan Kocherla, James S. Graydon, Theodore R. Holford, Gregory S. Makowski & John W. Goethe. (2016) Practical interpretation of CYP2D6 haplotypes: Comparison and integration of automated and expert calling. Clinica Chimica Acta 456, pages 7-14.
Crossref
Crossref
Adam S. Gordon, Robert S. Fulton, Xiang Qin, Elaine R. Mardis, Deborah A. Nickerson & Steve Scherer. (2016) PGRNseq. Pharmacogenetics and Genomics 26:4, pages 161-168.
Crossref
Crossref
Natchaya Vanwong, Nattawat Ngamsamut, Yaowaluck Hongkaew, Nopphadol Nuntamool, Apichaya Puangpetch, Montri Chamnanphon, Ananya Sinrachatanant, Penkhae Limsila & Chonlaphat Sukasem. (2016) Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels. Drug Metabolism and Pharmacokinetics 31:2, pages 156-162.
Crossref
Crossref
Jie Cai, Da-Peng Dai, Pei-Wu Geng, Shuang-Hu Wang, Hao Wang, Yun-Yun Zhan, Xiang-Xin Huang, Guo-Xin Hu & Jian-Ping Cai. (2016)
Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms
In Vitro
. Basic & Clinical Pharmacology & Toxicology 118:3, pages 190-199.
Crossref
Crossref
Wanqiong Qiao, Yao Yang, Robert Sebra, Geetu Mendiratta, Andrea Gaedigk, Robert J. Desnick & Stuart A. Scott. (2016) Long-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6. Human Mutation 37:3, pages 315-323.
Crossref
Crossref
Rashmi R Shah, Andrea Gaedigk, Adrián LLerena, Michel Eichelbaum, Julia Stingl & Robert L Smith. (2016) CYP450 genotype and pharmacogenetic association studies: a critical appraisal. Pharmacogenomics 17:3, pages 259-275.
Crossref
Crossref
Volker M. Lauschke & Magnus Ingelman-Sundberg. (2016) Precision Medicine and Rare Genetic Variants. Trends in Pharmacological Sciences 37:2, pages 85-86.
Crossref
Crossref
Greyson P Twist, Andrea Gaedigk, Neil A Miller, Emily G Farrow, Laurel K Willig, Darrell L Dinwiddie, Josh E Petrikin, Sarah E Soden, Suzanne Herd, Margaret Gibson, Julie A Cakici, Amanda K Riffel, J Steven Leeder, Deendayal Dinakarpandian & Stephen F Kingsmore. (2016) Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene, CYP2D6, from whole-genome sequences. npj Genomic Medicine 1:1.
Crossref
Crossref
Amanda K. Riffel, Mehdi Dehghani, Toinette Hartshorne, Kristen C. Floyd, J. Steven Leeder, Kevin P. Rosenblatt & Andrea Gaedigk. (2016) CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6*15 and *35 Genotyping. Frontiers in Pharmacology 6.
Crossref
Crossref
Mónica Acuña, Eric Pinto, Paulina Olivares & Carolina Ríos. (2016) Genetic Variants of Cytochrome <b><i>CYP2D6</i></b> in Two Mixed Chilean Populations. Human Heredity 82:1-2, pages 16-20.
Crossref
Crossref
Malgorzata Maciukiewicz, Venuja Sriretnakumar & Daniel J. Müller. 2016. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders. Genetic Influences on Response to Drug Treatment for Major Psychiatric Disorders
21
38
.
Daniel L. Hertz, Anna C. Snavely, Howard L. McLeod, Christine M. Walko, Joseph G. Ibrahim, Steven Anderson, Karen E. Weck, Gustav Magrinat, Oludamilola Olajide, Susan Moore, Rachel Raab, Daniel R. Carrizosa, Steven Corso, Garry Schwartz, Jeffrey M. Peppercorn, James P. Evans, David R. Jones, Zeruesenay Desta, David A. Flockhart, Lisa A. Carey & William J. IrvinJrJr. (2015)
In vivo
assessment of the metabolic activity of CYP2D6 diplotypes and alleles
. British Journal of Clinical Pharmacology 80:5, pages 1122-1130.
Crossref
Crossref
Andrea Gaedigk, Amanda K. Riffel & J. Steven Leeder. (2015) CYP2D6 Haplotype Determination Using Long Range Allele-Specific Amplification. The Journal of Molecular Diagnostics 17:6, pages 740-748.
Crossref
Crossref
Mary V. Relling & William E. Evans. (2015) Pharmacogenomics in the clinic. Nature 526:7573, pages 343-350.
Crossref
Crossref
T Lewis, J Dinh & JS Leeder. (2015) Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research. Clinical Pharmacology & Therapeutics 98:3, pages 309-320.
Crossref
Crossref
Jacob T Brown & Jeffrey R Bishop. (2015) Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability. Pharmacogenomics 16:13, pages 1513-1520.
Crossref
Crossref
Rui Chen, Haotian Wang, Jun Shi, Kai Shen & Pei Hu. (2015) Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. European Journal of Clinical Pharmacology 71:7, pages 835-841.
Crossref
Crossref
Gamze Bostankolu, Yavuz Ayhan, Fusun Cuhadaroglu & Mumin Kazım Yazıcı. (2014) Serotonin syndrome with a combination of aripiprazole and fluoxetine: a case report. Therapeutic Advances in Psychopharmacology 5:2, pages 138-140.
Crossref
Crossref
Andrea Gaedigk, Natalie Freeman, Toinette Hartshorne, Amanda K. Riffel, David Irwin, Jeffrey R. Bishop, Mark A. Stein, Jeffrey H. Newcorn, Lazara Karelia Montané Jaime, Mariana Cherner & J. Steven Leeder. (2015) SNP genotyping using TaqMan® technology: the CYP2D6*17 assay conundrum. Scientific Reports 5:1.
Crossref
Crossref
In-Wha Kim, Nayoung Han, Myeong Gyu Kim, Therasa Kim & Jung Mi Oh. (2015) Copy number variability analysis of pharmacogenes in patients with lymphoma, leukemia, hepatocellular, and lung carcinoma using The Cancer Genome Atlas data. Pharmacogenetics and Genomics 25:1, pages 1-7.
Crossref
Crossref
Jessica Tay-Sontheimer, Laura M Shireman, Richard P Beyer, Taurence Senn, Daniela Witten, Robin E Pearce, Andrea Gaedigk, Cletus L Gana Fomban, Justin D Lutz, Nina Isoherranen, Kenneth E Thummel, Oliver Fiehn, J Steven Leeder & Yvonne S Lin. (2014) Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics. Pharmacogenomics 15:16, pages 1947-1962.
Crossref
Crossref
H Fang, X Liu, J Ramírez, N Choudhury, M Kubo, H K Im, A Konkashbaev, N J Cox, M J Ratain, Y Nakamura & P H O'Donnell. (2014) Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. The Pharmacogenomics Journal 14:6, pages 564-572.
Crossref
Crossref
Deise C. Friedrich, Júlia P. Genro, Vinicius A. Sortica, Guilherme Suarez-Kurtz, Maria Elizabete de Moraes, Sergio D. J. Pena, Ândrea K. Ribeiro dos Santos, Marco A. Romano-Silva & Mara H. Hutz. (2014) Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population. PLoS ONE 9:10, pages e110691.
Crossref
Crossref
Andrea Gaedigk, Carles Garcia-Ribera, Hye-Eun Jeong, Jae-Gook Shin & Juanjo Hernandez-Sanchez. (2014)
Resolution of a clinical AmpliChip CYP450 Test™ no call: discovery and characterization of novel
CYP2D6*1
haplotypes
. Pharmacogenomics 15:9, pages 1175-1184.
Crossref
Crossref
Andrea GaedigkJ Steven Leeder. (2014)
CYP2D6
and pharmacogenomics: where does future research need to focus? Part 1: technical aspects
. Pharmacogenomics 15:4, pages 407-410.
Crossref
Crossref
Yao Yang, Inga Peter & Stuart A. Scott. (2014) Pharmacogenetics in Jewish populations. Drug Metabolism and Drug Interactions 29:4.
Crossref
Crossref
Andrea Gaedigk, Amanda K. Riffel, Belén García Berrocal, Virginia García Solaesa, Ignacio Dávila & María Isidoro-García. (2014) Characterization of a complex CYP2D6 genotype that caused an AmpliChip CYP450 Test® no-call in the clinical setting. Clinical Chemistry and Laboratory Medicine (CCLM) 52:6.
Crossref
Crossref